WHO issues guidance on safe implementation of AI in medicine

As drugmakers around the world  rush to embrace the potential of artificial intelligence (AI) in the design and development of new medications, the World Health Organization has urged caution.

A new  publication from the WHO outlines key regulatory considerations, emphasizing the importance of establishing “safety and effectiveness.”

The global health body has argued in favor of making appropriate systems rapidly available in order to boost access to medicines, and encouraging dialogue between developers, regulators, manufacturers, health workers, and patients to ensure the best outcomes.